Tenax Therapeutics (TENX) Total Liabilities (2011 - 2026)
Tenax Therapeutics (TENX) posted quarterly Total Liabilities of $8.1 million for Q2 2026, up 219.47% year-over-year from $2.5 million in Q2 2025, and down 4.87% on a QoQ basis from $8.5 million in Q1 2026.
Tenax Therapeutics (TENX) Total Liabilities (2011 - 2026) Analysis & Trends
Tenax Therapeutics has reported Total Liabilities for 15 years, with the latest figure at $8.1 million in Q2 2026.
- Total Liabilities for Q2 2026 came in at $8.1 million, up 219.47% year-over-year; the trailing twelve-month figure through Jun 2026 was $8.1 million (up 219.47% YoY), and the FY2025 annual result was $7.2 million, up 52.48% from the prior year.
- Total Liabilities eased to $8.1 million in Q2 2026, from $8.5 million in the prior quarter.
- Over five years, Total Liabilities peaked at $8.5 million in Q1 2026 and troughed at $602214.0 in Q3 2023.
- A 5-year average of $3.3 million and a median of $2.3 million in 2022 frame the typical range for Total Liabilities.
- The widest annual swing landed in 2023, when Total Liabilities sank 53.58%; it then jumped 325.38% in 2024.
- A 5-year view of Total Liabilities shows it stood at $1.9 million in 2022, then jumped by 87.61% to $3.6 million in 2023, then soared by 30.83% to $4.7 million in 2024, then soared by 52.48% to $7.2 million in 2025, then climbed by 12.81% to $8.1 million in 2026.
- Per Business Quant data, the three most recent Total Liabilities figures were $8.1 million in Q2 2026, $8.5 million in Q1 2026, and $7.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 10.03 Bn |
| 10 | Tenax Therapeutics | 78.47 Mn | 78.47 Mn | - | 8.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.07 Mn |
| Mar 31, 2026 | 8.49 Mn |
| Dec 31, 2025 | 7.16 Mn |
| Sep 30, 2025 | 6.60 Mn |
| Jun 30, 2025 | 2.53 Mn |
| Mar 31, 2025 | 2.77 Mn |
| Dec 31, 2024 | 4.69 Mn |
| Sep 30, 2024 | 2.56 Mn |
| Jun 30, 2024 | 1.74 Mn |
| Mar 31, 2024 | 2.03 Mn |
| Dec 31, 2023 | 3.59 Mn |
| Sep 30, 2023 | 602,214.00 |
| Jun 30, 2023 | 823,841.00 |
| Mar 31, 2023 | 989,301.00 |
| Dec 31, 2022 | 1.91 Mn |
| Sep 30, 2022 | 785,169.00 |
| Jun 30, 2022 | 1.57 Mn |
| Mar 31, 2022 | 2.13 Mn |
| Dec 31, 2021 | 1.75 Mn |
| Sep 30, 2021 | 1.67 Mn |